I. Introduction
Joint replacement surgeries are very commonly being performed even in developing countries, but these surgeries are associated with major blood loss intra-operatively as well as post-operatively to the tune of 700 to 2100 ml (1) . The soft tissues in and around the hip, notably the significant adipose tissue in the subdermal layers of the thigh, makes the patient undergoing hip replacement vulnerable to a significant amount of unrecognized blood loss during and after the operative procedure. In Total Knee Arthroplasty a tourniquet can be applied prior to the operation given the distal nature of the skin incision but the use of tourniquet leads to hyperfibrinolysis which in itself increases bleeding (2) . Despite immense improvements in surgical as well as anesthetic techniques major orthopedic surgeries like joint replacement surgeries are commonly associated with marked blood loss, and a subsequent need for blood transfusion is often encountered. Bleeding causes are multifactorial, increased fibrinolytic activity being one of them (3) .
Best efforts to maintain intra-operative hemostasis are taken by the treating surgeon and anesthesiologist in order to reduce bleeding into the post-operative period and for better visualization of surgical site. Unfortunately, the surgeons have no options for dealing with bleeding from vessels contained within bone, as neither electro-cautery nor suture ligation is effective at arresting the persistent oozing from cancellous bone. During Hip surgeries the femoral intramedullary canal and the periacetabular region contain a significant amount of cancellous bone which bleeds profusely leading to massive blood loss.
Other blood conservation techniques currently available are hypotensive anaesthesia, regional anaesthesia and use of erythropoietin; all of these have their own consequences and complications.Allogenic blood transfusion is currently the most effective and only available solution to compensate for blood loss but blood transfusion in itself is associated with haemolysis, immunological response activation, risks of disease transmission like (HIV, HbsAg etc.), transfusion-related acute lung injury and post-operative surgical site infection, as well as high medical costs and prolonged hospital stay. This leads to increase in cost burden to the patient. Thus creating the need for a new modality of blood conservation.
Tranexamic Acid has gained popularity in recent years to reduce this surgical blood loss in patients undergoing joint replacement surgeries.Tranexamic Acid enters the extra-vascular space around surgical site and accumulates in tissues for as long as 17 hours, being a synthetic derivative of the amino acid lysine, it exerts its anti-fibrinolytic activity by reversibly binding to plasminogen and blocking its interaction with fibrin thus delaying the dissolution of haemostatic fibrin, thereby preventing dissolution of the fibrin clots (4).The drug can be used intravenously in a weight-based manner (10-20 mg/kg), or administered 1gm intravenously at the start of surgery and repeated intravenously 8 th hourly for next two doses (5) .Despite the proven efficacy of the use of Tranexamic Acid in total joint replacement, there are still some concerns about the development of venous thromboembolism (VTE) after Tranexamic Acid is used, however recent studies have not shown any increase in incidence of VTE or renal complications post Tranexamic Acid administration (6) .
The primary objective of this double blinded case-Control study was to evaluate the role of Intravenous Tranexamic Acid therapy in reducing total blood loss in patients undergoing joint replacement surgeries.
II. Materials
The present investigation was a double blinded case Control study conducted from January 2015 to January 2016. It included 78 patients coming to orthopedic OPD or Emergency undergoing joint replacement surgery for any reason. By means of simple randomization patients were divided into two groups, Experimental and Control groups. Patients having a known history of thromboembolic disease, myocardial infarction, cerebrovascular disease, angina, coagulopathy, any liver or renal disease or any other source of active bleeding were excluded from the study. Patients with pre-operative hemoglobin more than 10mg/dl for males and 9mg/dl for females were included in this study after an informed and written consent The Experimental group included 37 patients out of which 16 underwent Hemiarthroplasty, 12 Total Hip Arthroplasty and 9 Total Knee Arthroplasty. The Control group consisted of 41 patients out of whom 18 underwent Hemiarthroplasty, 14 Total Hip Arthroplasty and 9 Total Knee Arthroplasty.
Drug Preparation and Administration:
Operating room nursing staff prepared two syringes one containing Tranexamic Acid (0.1 ml/kg) and another containing Normal Saline (0.1 ml/kg). He had no access to the details of the patient except their IPD number and Weight. He then randomized patients and gave one of the pre-filled syringes to the Anesthetist who injected the contents of the drug intravenously slowly at a rate of 1 ml/min starting at the incision time (for Total Hip Arthroplasty or Hemiarthroplasty) of surgery or 15 minutes before Tourniquet inflation (in case of Total Knee Arthroplasty) to the patient without knowing the content of the syringe. Post-operatively same syringe content was administered to the patient at 8 th hour and at 16 th hour from incision time by post-operative room nursing staff as per order of the operating room staff assigned for this study. The details of the record were kept by the operative room staff.
Method of Calculating Blood Loss:
1. A sensitive digital weighing machine was used to measure the weight of dry mop pieces and an average weight of dry mop pieces was taken as a standard and was compared to the weight of all used blood soaked mop pieces post-surgery in each case. The dry mop weight was subtracted from soaked mop weight giving the blood loss in mop. 2. The total output in suction container was subtracted from the total amount of fluid (Normal Saline) used to wash the surgical site to calculate the blood loss in suction. 3. Spillage was approximated by the operating surgeon. 4. Amount of collection in Romovac drain was calculated post-operatively till 2 nd post-op day when drain was removed. 5. Post-operatively hemoglobin and packed cell volume were done on day 1.
Statistical analysis was carried out using SPSS 22. Mann-Whitney U test was used to analyze the blood loss and hemoglobin of Experimental and Control group. The Experimental group consisted of 37 patients while Control group consisted of 41. The Experimental and Control were found to be matched statistically on the bases of both age and sex as shown in Table 1 .Total intra-operative blood loss was significantly lower in Experimental group in all three surgeries with the significant p value of 0.000 for Hemiarthroplasty, 0.015 for Total Knee Arthroplasty and 0.019 for Total Knee Arthroplasty as shown in Table 2 .
Tables And Results
The post-operative drain volume was also significantly lower in Experimental group in all surgeries considered in this study with the significant p value of 0.000 for Hemiarthroplasty, 0.013 for Total Knee Arthroplasty and 0.000 for Total Knee Arthroplasty as shown in Table 3 .The Total blood loss (sum of intra-operative loss and post-operative drain volume) was also found to be significantly lower in Experimental group with the p value of 0.000 for Hemiarthroplasty, 0.002 for Total Hip Arthroplasty and 0.000 for Total Knee Arthroplasty as shown in Table 4 -6.The mean fall in hemoglobin postoperative was also calculated by subtracting the pre-operative hemoglobin from post-operative hemoglobin.
Mean fall in hemoglobin was lower in Experimental group when compared to Control group with the significant p value of 0.001 for Hemiarthroplasty, 0.001 for Total Hip Arthroplasty and 0.019 for Total Knee Arthroplasty as shown in Table 7 .None of the patients experienced any adverse effects of Tranexamic Acid like nausea, itching, vomiting, diarrhea etc. None of the patients developed clinical signs of Deep Vein Thrombosis or any Thromboembolic phenomenon, though none of the patients were screened for the same.
III. Discussion Dose and Timing of Drug Administration:
There is a great diversity in the dose and time regimen of Tranexamic Acid in different studies ranging from single dose regimen to three dose regimen eg. Ralley FE et al (7) used a single intra-operative dose of 20 mg/kg while Motififiard M et al (8) used two dose regimen of 500 mg Tranexamic Acid. Hiippala ST et al (9) Evaluate the role of Tranexamic Acid in Joint Replacement Surgeries DOI: 10.9790/0853-1605030308 www.iosrjournals.org 6 | Page used a three dose regimen with 10 mg/kg intra-operative and two post-operative doses, Sabatini L et al (10) used 10 mg/kg bolus with infusion and repeat dose after 3 hours, Maniar RN et al (11) compared three different regimen (intra-operative dose before tourniquet deflation, additional pre-operative dose and additional postoperative dose) and found that minimum two dose regimen is needed for significant reduction in blood loss. Pharmacokinetic studies indicate that the therapeutic level of Tranexamic Acid stays in body for approximately 8 hours and this covers the period of hyperfibrinolysis in cases of increased blood loss (12) . That is the sole reason of repeat dose at 8 hours interval in our study. The dose regimen used in our study included 10 mg/kg dose pre-operative and repeated twice postoperatively at 8 hours interval is consistent with Niskanen RO et al (13) which showed that average blood loss in Experimental group of Total Hip Arthroplasty to be 792 ml and in Control group it was 1102 ml (p = 0.03). In our study it was 647.68 ml and 842.80 ml (p=0.002) in Experimental and Control group respectively.Emara et al (14) compared intravenous Tranexamic Acid with placebo group and calculated total blood loss in Hemiarthroplasty to be 640±25 ml and 1100±30 ml in Experimental and Control group respectively with a significant value of p<0.05 which is consistent with our results of 439±40 ml and 593±60 ml with a p value of 0.000. Thus proving that Tranexamic Acid significantly reduces blood loss in Hemiarthroplasty.Rajesh N. Maniar et al (11) in their three dose regimen observed average blood loss of 688 ml in Experimental and 1097 ml in Control group in patients undergoing Total Knee Arthroplasty with significant p value of 0.001, when compared with our study in which blood loss was 623 ml and 923 ml in Experimental and Control group respectively with a p value of 0.000. Our results for Total Knee Arthroplasty are consistent with their study.We found that 10mg/kg is a sufficient dose to reduce blood loss and there is no additional benefit of increasing the dose or changing the dosage regimen.
Tourniquet:
In today's setup Total Knee Arthroplasty surgeries are done under tourniquet but many authors have stated that the application of a pneumatic tourniquet enhances fibrinolytic activity several times above the basal level in the extremity. The acceleration of fibrinolysis is due to tissue plasminogen activator released from the vascular endothelium. The release is triggered by anoxia or venous distension. It is logical to assume that this local phenomenon serves as a protective mechanism against vascular thrombosis during inflation of the tourniquet (15) .
Apparently, this local acceleration of fibrinolysis and the haemostatic consequences last considerably longer and are more prone to post-operative bleeding than anticipated. Tourniquet was used in every case of Total Knee Arthroplasty in which dose of Tranexamic Acid was given 15 minutes prior to inflation of tourniquet. Hiippala ST et al (9) found that blood loss volume in Total Knee Arthroplasty after using tourniquet was 1509 ± 643 ml and 689 ± 289 ml (p < 0.0001), in our study it was 923.55±101.47 ml and 623.35±45.35 ml (p=0.000) in Control and Experimental group respectively. Our results were consistent with their study with significant reduction in blood loss in Experimental group compared to Control group.We found that despite the use of tourniquet there is significant blood loss in patients undergoing total knee replacement and tranexamic acid significantly reduces the blood loss despite the use of tourniquet.
Blood Loss:
Joint replacement surgeries are associated with major blood loss. In Hemiarthroplasty it is approximated at 400-500 ml (16) , that in Total Hip Arthroplasty is assumed to be ranging from 700-1500 ml (17) and for Total Knee Arthroplasty several authors have stated different volumes, Sehat KR et al (18) stated blood loss to be 800-1200 ml, Benoni G et al. (19) as 800-1800 ml, Georgiadis AG et al. (20) as 500-2000 ml . n Hemiarthroplasty, Emara WM et al (14) found that total blood loss with 10 mg/kg bolus dose at incision and continuous infusion of 5 mg/kg/hr till end of surgery to be 640±25 ml when compared to Control group (1100±30 ml). In our study we found the blood loss to be 439.34±40.80 ml in Experimental and 593.11±60.61 ml in Control group. Our results are consistent with their study as there is significant reduction in blood loss in Experimental group, though there is significantly less blood loss in both groups in our study which may be due to different dose regimen used by them.
In Total Hip Arthroplasty surgeries Niskanen RO et al (13) found that there was significant reduction in blood loss (792 ml and 1102 ml in Experimental and Control group respectively) by using a three dose regimen of 10 mg/kg at 0, 8 and 16 hours. We found similar results with same dose regimen. In our study blood loss in Experimental group was 647.35±45.35 ml and 923.55±101.47 ml in Control group respectively (p=0.002). Our results are consistent with their study. In patients undergoing Total Knee Arthroplasty, Iwai T et al (21) found that with single dose of Tranexamic Acid the blood loss was 1246.6 ml whereas with a two dose regimen it was 915.3 ml when compared with Control group (1538.3 ml). Hiippala ST et al (9) 
Hemoglobin:
In our study we compared the fall in hemoglobin post-operatively compared to pre-operative hemoglobin and found a significantly higher hemoglobin post-operatively ( Sarzaeem MM et al found that intravenous route was more effective in reducing the post-operative hemoglobin drop when compared to topical or intra-articular route (24) .All these studies state that use Tranexamic Acid intravenously significantly leads to higher post-operative hemoglobin compared to placebo which is consistent with our study. A minimum of two dose regimen should be administered to significantly reduce blood loss volume. When we compared our study with other studies we found that the best regimen for most reduction in blood volume is a three dose regimen with dose of 10-15 mg/kg.
Strength and Limitation of Study:
Our study included Hemiarthroplasty, total hip and Total Knee Arthroplastys while most of the authors only include one surgery. We compared each surgery with its Experimental and Control group as surgical exposure is different for all surgeries. All surgeries were performed by two specialized surgeons of same stature. Surgical time was almost same in both groups of same replacement surgery.There are a few limitations in our study, small sample size being one of them. Secondly, patients were not screened for complications like deep vein thrombosis or venous thromboembolism. Cost benefit ratio was also not calculated.
IV. Conclusion
Tranexamic acid is an effective, efficient and a cheap drug for conservation of blood loss. It can reduce blood loss in all Orthopaedic surgeries without increasing cost burden on patient. It can also provide a better visual field due to reduced bleeding.
